DJ Arix Bioscience PLC: Portfolio Company Aura Biosciences Announces Closing of USD99 million Public Offering of Common Stock
Arix Bioscience PLC (ARIX)
Correction: Portfolio Company Aura Biosciences Announces Closing of USD99 million Public Offering of Common Stock
13-Nov-2023 / 16:00 GMT/BST
=----------------------------------------------------------------------------------------------------------------------
Arix Bioscience plc
Portfolio Company Aura Biosciences Announces Closing of USD99 million Public Offering of Common Stock
LONDON, 13 November 2023: Arix Bioscience plc ("Arix" or the "Company") (LSE: ARIX), a transatlantic venture capital
company focused on investing in breakthrough biotechnology companies, notes that its Core Portfolio company, Aura
Biosciences (NASDAQ: AURA) ("Aura"), has announced the closing of its underwritten public offering of 11,000,000 shares
of its common stock at a price to the public of USD9.00 per share.
Aura received net proceeds from the Offering, after deducting the underwriting discounts and commissions and estimated
offering expenses, of approximately USD92.6 million. Aura intends to use the net proceeds from the Offering, together
with its existing cash, cash equivalents and marketable securities to advance the clinical development of belzupacap
sarotalocan for the treatment of choroidal melanoma and choroidal metastasis, to develop the platform and for general
corporate purposes. Aura believes that the net proceeds from this offering, together with its existing cash, cash
equivalents and marketable securities, will enable it to fund its operating expenses and capital expenditure
requirements into the second half of 2026.
Arix holds 1,508,483 shares in Aura. The holding value of these shares will continue to be determined by the market
price of Aura's shares.
The full text from Aura's announcement can be accessed on the Aura Biosciences website here: https://
ir.aurabiosciences.com/press-releases
[ENDS]
Enquiries
For more information on Arix, please contact:
Arix Bioscience plc
+44 (0)20 7290 1050
ir@arixbioscience.com
Powerscourt Group
Sarah MacLeod, Ibrahim Khalil, Nick Johnson
+44 (0)20 7250 1446
arix@powerscourt-group.com
About Arix Bioscience plc
Arix Bioscience plc is a transatlantic venture capital company focused on investing in breakthrough biotechnology
companies around cutting-edge advances in life sciences.
We collaborate with exceptional entrepreneurs and provide the capital, expertise, and global networks to help
accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this
exciting growth phase of our industry to a broader range of investors. www.arixbioscience.com
=----------------------------------------------------------------------------------------------------------------------
Dissemination of a Regulatory Announcement, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
=----------------------------------------------------------------------------------------------------------------------
ISIN: GB00BD045071
Category Code: MSCM
TIDM: ARIX
LEI Code: 213800OVT3AHQCXNIX43
OAM Categories: 3.1. Additional regulated information required to be disclosed under the laws of a Member State
Sequence No.: 284573
EQS News ID: 1772109
End of Announcement EQS News Service
=------------------------------------------------------------------------------------
Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1772109&application_name=news
(END) Dow Jones Newswires
November 13, 2023 11:00 ET (16:00 GMT)
